Modulation of human motor cortex excitability by single doses of amantadine

Neuropsychopharmacology

Volumn 31, Issue 12, 2006, Pages 2758-2766

  Reis, Janine ^a   John, Daniel ^a   Heimeroth, Antje ^a   Mueller, Hans Helge ^a   Oertel, Wolfgang H ^a   Arndt, Torsten ^b   Rosenow, Felix ^a  

^a PHILIPPS UNIVERSITY MARBURG   (Germany)

^b Bioscientia Center for Human Genetics   (Germany)

Author keywords

Amantadine; GABA; Glutamate; Motor cortex excitability; Parkinson's disease; Transcranial magnetic stimulation

Indexed keywords

AMANTADINE;

ADULT; AMPLITUDE MODULATION; ARTICLE; BRAIN DEPTH STIMULATION; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL TRIAL; COGNITIVE DEFECT; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG INDUCED HEADACHE; EVALUATION; FEMALE; HUMAN; INHIBITION KINETICS; LATENT PERIOD; MALE; MOTOR CORTEX; MUSCLE; NEUROMODULATION; NORMAL HUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RESTLESSNESS; SINGLE DRUG DOSE; SPINAL CORD; TRANSCRANIAL MAGNETIC STIMULATION; VISUAL DISORDER;

ADULT; AMANTADINE; ANTIPARKINSON AGENTS; CROSS-OVER STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; EFFERENT PATHWAYS; ELECTROMYOGRAPHY; EVOKED POTENTIALS, MOTOR; EXCITATORY AMINO ACID ANTAGONISTS; FEMALE; GAMMA-AMINOBUTYRIC ACID; GLUTAMIC ACID; HUMANS; MALE; MOTOR CORTEX; MUSCLE, SKELETAL; NEURAL INHIBITION; NEURAL PATHWAYS; RECEPTORS, N-METHYL-D-ASPARTATE; SYNAPTIC TRANSMISSION; TRANSCRANIAL MAGNETIC STIMULATION;

EID: 33751097462     PISSN: 0893133X     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.npp.1301122     Document Type: Article

References (61)

1. Aoki FY, Sitar DS (1985). Amantadine kinetics in healthy elderly men: implications for influenza prevention. Clin Pharmacol Ther 37: 137-144.
2. Aoki FY, Sitar DS, Ogilvie RI (1979). Amantadine kinetics in healthy young subjects after long-term dosing. Clin Pharmacol Ther 26: 729-736.
3. Arndt T, Guessregen B, Hohl A, Reis J (2005). Determination of serum amantadine by liquid chromatography-tandem mass spectrometry. Clin Chim Acta 359: 125-131.
4. Berardelli A, Rona S, Inghilleri M, Manfredi M (1996). Cortical inhibition in Parkinson's disease. A study with paired magnetic stimulation. Brain 119(Part 1): 71-77.
5. Blanpied TA, Clarke RJ, Johnson JW (2005). Amantadine inhibits NMDA receptors by accelerating channel closure during channel block. J Neurosci 25: 3312-3322.
6. Brasil-Neto JP, McShane LM, Fuhr P, Hallett M, Cohen LG (1992). Topographic mapping of the human motor cortex with magnetic stimulation: factors affecting accuracy and reproducibility. Electroencephalogr Clin Neurophysiol 85: 9-16.
7. Butefisch CM, Davis BC, Sawaki L, Waldvogel D, Classen J, Kopylev L et al (2002). Modulation of use-dependent plasticity by d-amphetamine. Ann Neurol 51: 59-68.
8. Chen R, Kumar S, Garg RR, Lang AE (2001). Impairment of motor cortex activation and deactivation in Parkinson's disease. Clin Neurophysiol 112: 600-607.
9. Deep P, Dagher A, Sadikot A, Gjedde A, Cumming P (1999). Stimulation of dopa decarboxylase activity in striatum of healthy human brain secondary to NMDA receptor antagonism with a low dose of amantadine. Synapse 34: 313-318.
10. DiLazzaro V, Restuccia D, Oliviero A, Profice P, Ferrara L, Insola A et al (1998). Magnetic transcranial stimulation at intensities below active motor threshold activates intracortical inhibitory circuits. Exp Brain Res 119: 265-268.
11. Farnebo LO, Fuxe K, Goldstein M, Hamberger B, Ungerstedt U (1971). Dopamine and noradrenaline releasing action of amantadine in the central and peripheral nervous system: a possible mode of action in Parkinson's disease. Eur J Pharmacol 16: 27-38.
12. Fuhr P, Agostino R, Hallett M (1991). Spinal motor neuron excitability during the silent period after cortical stimulation. Electroencephalogr Clin Neurophysiol 81: 257-262.
13. Hadj Tahar A, Blanchet PJ, Doyon J (2004). Motor-learning impairment by amantadine in healthy volunteers. Neuropsychopharmacology 29: 187-194.
14. Hallett M (1995). Transcranial magnetic stimulation. Negative effects. Adv Neurol 67: 107-113.
15. Hamer HM, Reis J, Mueller HH, Knake S, Overhof M, Oertel WH et al (2005). Motor cortex excitability in focal epilepsies not including the primary motor area - a TMS study. Brain 128: 811-818.
16. Heikkila RE, Cohen G (1972). Evaluation of amantadine as a releasing agent or uptake blocker for H 3-dopamine in rat brain slices. Eur J Pharmacol 20: 156-160.
17. Hess CW, Mills KR, Murray NM, Schriefer TN (1987). Excitability of the human motor cortex is enhanced during REM sleep. Neurosci Lett 82: 47-52.
18. Jackisch R, Link T, Neufang B, Koch R (1992). Studies on the mechanism of action of the antiparkinsonian drugs memantine and amantadine: no evidence for direct dopaminomimetic or antimuscarinic properties. Arch Int Pharmacodyn Ther 320: 21-42.
19. Kornhuber J, Bormann J, Hubers M, Rusche K, Riederer P (1991). Effects of the 1-amino-adamantanes at the MK-801-binding site of the NMDA-receptor-gated ion channel: a human postmortem brain study. Eur J Pharmacol 206: 297-300.
20. Kornhuber J, Quack G, Danysz W, Jellinger K, Danielczyk W, Gsell W et al (1995). Therapeutic brain concentration of the NMDA receptor antagonist amantadine. Neuropharmacology 34: 713-721.
21. Kornhuber J, Schoppmeyer K, Riederer P (1993a). Affinity of 1-aminoadamantanes for the sigma binding site in post-mortem human frontal cortex. Neurosci Lett 163: 129-131.
22. Kornhuber J, Weller M, Riederer P (1993b). Glutamate receptor antagonists for neuroleptic malignant syndrome and akinetic hyperthermic parkinsonian crisis. J Neural Transm Park Dis Dement Sect 6: 63-72.
23. Kujirai T, Caramia MD, Rothwell JC, Day BL, Thompson PD, Ferbert A et al (1993). Corticocortical inhibition in human motor cortex. J Physiol 471: 501-519.
24. Lefaucheur JP (2005). Motor cortex dysfunction revealed by cortical excitability studies in Parkinson's disease: influence of antiparkinsonian treatment and cortical stimulation. Clin Neurophysiol 116: 244-253.
25. Liepert J, Schwenkreis P, Tegenthoff M, Malin JP (1997). The glutamate antagonist riluzole suppresses intracortical facilitation. J Neural Transm 104: 1207-1214.
26. Lin TI, Heider H, Schroeder C (1997). Different modes of inhibition by adamantane amine derivatives and natural polyamines of the functionally reconstituted influenza virus M2 proton channel protein. J Gen Virol 78(Part 4): 767-774.
27. Lupp A, Lucking CH, Koch R, Jackisch R, Feuerstein TJ (1992). Inhibitory effects of the antiparkinsonian drugs memantine and amantadine on N-methyl-D-aspartate-evoked acetylcholine release in the rabbit caudate nucleus in vitro. J Pharmacol Exp Ther 263: 717-724.
28. Matsubayashi H, Swanson KL, Albuquerque EX (1997). Amantadine inhibits nicotinic acetylcholine receptor function in hippocampal neurons. J Pharmacol Exp Ther 281: 834-844.
29. McDonnell MN, Orekhov Y, Ziemann U (2006). The role of GABA(B) receptors in intracortical inhibition in the human motor cortex. Exp Brain Res [E-pub ahead of print].
30. Mizoguchi K, Yokoo H, Yoshida M, Tanaka T, Tanaka M (1994). Amantadine increases the extracellular dopamine levels in the striatum by re-uptake inhibition and by N-methyl-D-aspartate antagonism. Brain Res 662: 255-258.
31. Moresco RM, Volonte MA, Messa C, Gobbo C, Galli L, Carpinelli A et al (2002). New perspectives on neurochemical effects of amantadine in the brain of parkinsonian patients: a PET-[(11)C] raclopride study. J Neural Transm 109: 1265-1274.
32. Nakamura H, Kitagawa H, Kawaguchi Y, Tsuji H (1997). Intracortical facilitation and inhibition after transcranial magnetic stimulation in conscious humans. J Physiol 498(Part 3): 817-823.
33. Nakanishi H, Ukai K, Nakagawa T, Watanabe S, Kamata O, Yamamoto K (1990). Enhancement of NMDA receptor-mediated synaptic potential evoked in rat medial-amygdala neuron following olfactory bulbectomy. Brain Res 532: 69-75.
34. Northover BJ (1994). Effect of pre-treating rat atria with potassium channel blocking drugs on the electrical and mechanical responses to phenylephrine. Biochem Pharmacol 47: 2163-2169.
35. Oldfield RC (1971). The assessment and analysis of handedness: the Edinburgh inventory. Neuropsychologia 9: 97-113.
36. Parkes D (1974). Amantadine. Adv Drug Res 8: 11-81.
37. Parsons CG, Panchenko VA, Pinchenko VO, Tsyndrenko AY, Krishtal OA (1996). Comparative patch-clamp studies with freshly dissociated rat hippocampal and striatal neurons on the NMDA receptor antagonistic effects of amantadine and memantine. Eur J Neurosci 8: 446-454.
38. Pascual-Leone A, Cohen LG, Brasil-Neto JP, Hallett M (1994). Non-invasive differentiation of motor cortical representation of hand muscles by mapping of optimal current directions. Electroencephalogr Clin Neurophysiol 93: 42-48.
39. Pierantozzi M, Palmieri MG, Marciani MG, Bernardi G, Giacomini P, Stanzione P (2001). Effect of apomorphine on cortical inhibition in Parkinson's disease patients: a transcranial magnetic stimulation study. Exp Brain Res 141: 52-62.
40. Priori A, Berardelli A, Inghilleri M, Accornero N, Manfredi M (1994). Motor cortical inhibition and the dopaminergic system. Pharmacological changes in the silent period after transcranial brain stimulation in normal subjects, patients with Parkinson's disease and drug-induced parkinsonism. Brain 117(Part 2): 317-323.
41. Reis J, Tergau F, Hamer HM, Muller HH, Knake S, Fritsch B et al (2002). Topiramate selectively decreases intracortical excitability in human motor cortex. Epilepsia 43: 1149-1156.
42. Reis J, Wentrup A, Hamer HM, Mueller HH, Knake S, Tergau F et al (2004). Levetiracetam influences human motor cortex excitability mainly by modulation of ion channel function - a TMS study. Epilepsy Res 62: 41-51.
43. Schwenkreis P, Liepert J, Witscher K, Fischer W, Weiller C, Malin JP et al (2000). Riluzole suppresses motor cortex facilitation in correlation to its plasma level. A study using transcranial magnetic stimulation. Exp Brain Res 135: 293-299.
44. Schwenkreis P, Witscher K, Janssen F, Addo A, Dertwinkel R, Zenz M et al (1999). Influence of the N-methyl-D-aspartate antagonist memantine on human motor cortex excitability. Neurosci Lett 270: 137-140.
45. Schwenkreis P, Witscher K, Pleger B, Malin JP, Tegenthoff M (2005). The NMDA antagonist memantine affects training induced motor cortex plasticity - a study using transcranial magnetic stimulation. BMC Neurosci 12: 35.
46. Shannon KM, Goetz CG, Carroll VS, Tanner CM, Klawans HL (1987). Amantadine and motor fluctuations in chronic Parkinson's disease. Clin Neuropharmacol 10: 522-526.
47. Siebner HR, Dressnandt J, Auer C, Conrad B (1998). Continuous intrathecal baclofen infusions induced a marked increase of the transcranially evoked silent period in a patient with generalized dystonia. Muscle Nerve 21: 1209-1212.
48. Stoof JC, Booij J, Drukarch B, Wolters EC (1992). The anti-parkinsonian drug amantadine inhibits the N-methyl-D-aspartic acid-evoked release of acetylcholine from rat neostriatum in a non-competitive way. Eur J Pharmacol 213: 439-443.
49. Takahashi T, Yamashita H, Zhang YX, Nakamura S (1996). Inhibitory effect of MK-801 on amantadine-induced dopamine release in the rat striatum. Brain Res Bull 41: 363-367.
50. Takeda M, Pekosz A, Shuck K, Pinto LH, Lamb RA (2002). Influenza a virus M2 ion channel activity is essential for efficient replication in tissue culture. J Virol 76: 1391-1399.
51. Tergau F, Wanschura V, Canelo M, Wischer S, Wassermann EM, Ziemann U et al (1999). Complete suppression of voluntary motor drive during the silent period after transcranial magnetic stimulation. Exp Brain Res 124: 447-454.
52. Togo Y, Hornick RB, Dawkins Jr AT (1968). Studies on induced influenza in man. I. Double-blind studies designed to assess prophylactic efficacy of amantadine hydrochloride against a2/Rockville/1/65 strain. JAMA 203: 1089-1094.
53. Verhagen ML, Del Dotto P, van den MP, Fang J, Mouradian MM, Chase TN (1998). Amantadine as treatment for dyskinesias and motor fluctuations in Parkinson's disease. Neurology 50: 1323-1326.
54. Vernier VG, Harmon JB, Stump JM, Lynes TE, Marvel JP, Smith DH (1969). The toxicologic and pharmacologic properties of amantadine hydrochloride. Toxicol Appl Pharmacol 15: 642-665.
55. Werhahn KJ, Kunesch E, Noachtar S, Benecke R, Classen J (1999). Differential effects on motorcortical inhibition induced by blockade of GABA uptake in humans. J Physiol 517(Part 2): 591-597.
56. Ziemann U, Bruns D, Paulus W (1996c). Enhancement of human motor cortex inhibition by the dopamine receptor agonist pergolide: evidence from transcranial magnetic stimulation. Neurosci Lett 208: 187-190.
57. Ziemann U, Chen R, Cohen LG, Hallett M (1998). Dextromethorphan decreases the excitability of the human motor cortex. Neurology 51: 1320-1324.
58. Ziemann U, Lonnecker S, Steinhoff BJ, Paulus W (1996a). Effects of antiepileptic drugs on motor cortex excitability in humans: a transcranial magnetic stimulation study. Ann Neurol 40: 367-378.
59. Ziemann U, Lonnecker S, Steinhoff BJ, Paulus W (1996b). The effect of lorazepam on the motor cortical excitability in man. Exp Brain Res 109: 127-135.
60. Ziemann U, Tam A, Butefisch C, Cohen LG (2002). Dual modulating effects of amphetamine on neuronal excitability and stimulation-induced plasticity in human motor cortex. Clin Neurophysiol 113: 1308-1315.
61. Ziemann U, Tergau F, Bruns D, Baudewig J, Paulus W (1997). Changes in human motor cortex excitability induced by dopaminergic and anti-dopaminergic drugs. Electroencephalogr Clin Neurophysiol 105: 430-437.